The transcription factor GATA1 and the histone methyltransferase SET7 interact to promote VEGF-mediated angiogenesis and tumor growth and predict clinical outcome of breast cancer

Oncotarget

Volumn 7, Issue 9, 2016, Pages 9859-9875

  Zhang, Yanan ^a,b   Liu, Jie ^a   Lin, Jing ^c   Zhou, Lei ^d   Song, Yuhua ^e   Wei, Bo ^c   Luo, Xiaoli ^a   Chen, Zhida ^a,c   Chen, Yingjie ^a,e   Xiong, Jiaxiu ^a,c   Xu, Xiaojie ^a   Ding, Lihua ^a   Ye, Qinong ^a,b  

^a BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

^b DALIAN MEDICAL UNIVERSITY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e QINGDAO UNIVERSITY   (China)

Author keywords

Angiogenesis; GATA1; SET7; Tumor growth; VEGF

Indexed keywords

HISTONE METHYLTRANSFERASE; HISTONE METHYLTRANSFERASE SET7; RNA POLYMERASE II; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR IIB; UNCLASSIFIED DRUG; VASCULOTROPIN; GATA1 PROTEIN, HUMAN; HISTONE LYSINE METHYLTRANSFERASE; SETD7 PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER PATIENT; CELL MIGRATION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DISEASE COURSE; DRUG TARGETING; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MCF 7 CELL LINE; MICROVASCULATURE; MOUSE; NONHUMAN; NUDE MOUSE; PREDICTION; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION REGULATION; TUMOR GROWTH; TUMOR VASCULARIZATION; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; BREAST TUMOR; CELL MOTION; CHICK EMBRYO; GENETICS; HEK293 CELL LINE; MCF-7 CELL LINE; METABOLISM; MIDDLE AGED; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR CELL LINE; VASCULARIZATION;

ADULT; AGED; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHICK EMBRYO; FEMALE; GATA1 TRANSCRIPTION FACTOR; HEK293 CELLS; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MCF-7 CELLS; MICE; MICE, NUDE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; RNA POLYMERASE II; TRANSCRIPTION FACTOR TFIIB; TRANSCRIPTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84961589836     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7126     Document Type: Article

References (50)

1. Nishida N, Yano H, Nishida T, Kamura T, Kojiro M. Angiogenesis in cancer. Vasc Health Risk Manag. 2006; 2:213-219.
2. McDougall SR, Anderson ARA, Chaplain MAJ. Mathematical modelling of dynamic adaptive tumour-induced angiogenesis: clinical implications and therapeutic targeting strategies. J Theor Biol. 2006; 7:564-589.
3. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008; 8:579-591.
4. Price DJ, Miralem T, Jiang S, Steinberg R, Avraham H. Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ. 2001; 12:129-135.
5. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003; 9:669-676.
6. Claffey KP, Robinson GS. Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis. Cancer Metastasis Rev. 1996; 15:165-176.
7. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology. 2005; 69:4-10.
8. Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M, Matsubara I, Vinante O, Bonoldi E, Boracchi P, Gatti C, Suzuki H, Tominaga T. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst. 1997; 89:139-147.
9. Liu ZQ, Fang JM, Xiao YY, Zhao Y, Cui R, Hu F, Xu Q. Prognostic role of vascular endothelial growth factor in prostate cancer: a systematic review and meta-analysis. Int J Clin Exp Med. 2015; 8:2289-2298.
10. Grothey A, Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol. 2009; 6:507-518.
11. Pages G, Pouyssegur J. Transcriptional regulation of the Vascular Endothelial Growth Factor gene-a concert of activating factors. Cardiovasc Res. 2005; 65:564-573.
12. Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer. 2013; 13:871-882.
13. Pore N, Liu S, Shu HK, Li B, Haas-Kogan D, Stokoe D, Milanini-Mongiat J, Pages G, O'Rourke DM, Bernhard E, Maity A. Sp1 is involved in Akt-mediated induction of VEGF expression through an HIF-1-independent mechanism. Mol Biol Cell. 2004; 15:4841-4853.
14. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996; 16:4604-4613.
15. Wei D, Le X, Zheng L, Wang L, Frey JA, Gao AC, Peng Z, Huang S, Xiong HQ, Abbruzzese JL, Xie K. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene. 2003; 22:319-329.
16. Lopes FL, Desmarais J, Ledoux S, Gevry NY, Lefevre P, Murphy BD. Transcriptional regulation of uterine vascular endothelial growth factor during early gestation in a carnivore model, Mustela vison. J Biol Chem. 2006; 281:24602-24611.
17. Ziel KA, Campbell CC, Wilson GL, Gillespie MN. Ref-1/Ape is critical for formation of the hypoxia-inducible transcriptional complex on the hypoxic response element of the rat pulmonary artery endothelial cell VEGF gene. FASEB J. 2004; 18:986-988.
18. Jung JE, Lee HG, Cho IH, Chung DH, Yoon SH, Yang YM, Lee JW, Choi S, Park JW, Ye SK, Chung MH. STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells. FASEB J. 2005; 19:1296-1298.
19. Ansari KI, Kasiri S, Mandal SS. Histone methylase MLL1 has critical roles in tumor growth and angiogenesis and its knockdown suppresses tumor growth in vivo. Oncogene. 2013; 32:3359-3370.
20. Kashyap V, Ahmad S, Nilsson EM, Helczynski L, Kenna S, Persson JL, Gudas LJ, Mongan NP. The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancer. Mol Oncol. 2013; 7:555-566.
21. Zheng R, Blobel GA. GATA Transcription Factors and Cancer. Genes Cancer. 2010; 1:1178-1188. doi: 10.1177/1947601911404223.
22. Shimizu R, Engel JD, Yamamoto M. GATA1-related leukaemias. Nat Rev Cancer. 2008; 8:279-287.
23. Boidot R, Vegran F, Jacob D, Chevrier S, Cadouot M, Feron O, Solary E, Lizard-Nacol S. The transcription factor GATA-1 is overexpressed in breast carcinomas and contributes to survivin upregulation via a promoter polymorphism. Oncogene. 2010; 29:2577-2584.
24. Li Y, Ke Q, Shao Y, Zhu G, Li Y, Geng N, Jin F, Li F. GATA1 induces epithelial-mesenchymal transition in breast cancer cells through PAK5 oncogenic signaling. Oncotarget. 2015; 6:4345-4356. doi: 10.18632/oncotarget.2999.
25. Gu B, Lee MG. Histone H3 lysine 4 methyltransferases and demethylases in self-renewal and differentiation of stem cells. Cell Biosci. 2013; 3:39.
26. Keating ST, El-Osta A. Transcriptional regulation by the Set7 lysine methyltransferase. Epigenetics. 2013; 8:361-372.
27. Ucuian AA, Gassman AA, East AT, Greisler HP. Molecular mediators of angiogenesis. J Burn Care Res. 2010; 31:158-175.
28. Fischle W. One, two, three: how histone methylation is read. Epigenetics. 2012; 4:641-653.
29. Greer EL, Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet. 2012; 13:343-357.
30. Xiao B, Jing C, Wilson JR, Walker PA, Vasisht N, Kelly G, Howell S, Taylor IA, Blackburn GM, Gamblin SJ. Structure and catalytic mechanism of the human histone methyltransferase SET7/9. Nature. 2003; 421:652-656.
31. Mishra BP, Ansari KI, Mandal SS. Dynamic association of MLL1, H3K4 trimethylation with chromatin and Hox gene expression during the cell cycle. FEBS J. 2009; 276:1629-1640.
32. Schneider J, Wood A, Lee JS, Schuster R, Dueker J, Maguire C, Swanson SK, Florens L, Washburn MP, Shilatifard A. Molecular regulation of histone H3 trimethylation by COMPASS and the regulation of gene expression. Mol Cell. 2005; 19:849-856.
33. Thomas MC, Chiang CM. The general transcription machinery and general cofactors. Crit Rev Biochem Mol Biol. 2006; 41:105-178.
34. Glossop JA, Dafforn TR, Roberts SG. A conformational change in TFIIB is required for activator-mediated assembly of the preinitiation complex. Nucleic Acids Res. 2004; 32:1829-1835.
35. Lee TH, Seng S, Sekine M, Hinton C, Fu Y, Avraham HK, Avraham S. Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1. PLoS Med. 2007; 4:186.
36. Liang Y, Brekken RA, Hyder SM. Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones. Endocr Relat Cancer. 2006; 13:905-919.
37. Gregory T, Yu C, Ma A, Orkin SH, Blobel GA, Weiss MJ. GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating bcl-xL expression. Blood. 1999; 94:87-96.
38. Bartunek P, Kralova J, Blendinger G, Dvorak M, Zenke M. GATA-1 and c-myb crosstalk during red blood cell differentiation through GATA-1 binding sites in the c-myb promoter. Oncogene. 2003; 22:1927-1935.
39. Rylski M, Welch JJ, Chen YY, Letting DL, Chodosh JA, Blobel GA, Weiss MJ. GATA-1-mediated proliferation arrest during erythroid maturation. Mol Cell Biol. 2003; 23:5031-5042.
40. Vaissiere T, Sawan C, Herceg Z. Epigenetic interplay between histone modifications and DNA methylation in gene silencing. Mutat Res. 2008; 659:40-48.
41. Chi P, Allis CD, Wang GG. Covalent histone modifications-miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer. 2010; 10:457-469.
42. Jones PA. At the tipping point for epigenetic therapies in cancer. J Clin Invest. 2014; 124:14-16.
43. Kurash JK, Lei H, Shen Q, Marston WL, Granda BW, Fan H, Wall D, Li E, Gaudet F. Methylation of p53 by Set7/9 mediates p53 acetylation and activity in vivo. Mol Cell. 2008; 29:392-400.
44. Subramanian K, Jia D, Kapoor-vazirani P, Powell DR, Collins RE, Sharma D, Peng J, Cheng X, Vertino PM. Regulation of estrogen receptor alpha by the SET7 lysine methyltransferase. Mol Cell. 2008; 30:336-347.
45. Shimoyamada H, Yazawa T, Sato H, Okudela K, Ishii J, Sakaeda M, Kashiwagi K, Suzuki T, Mitsui H, Woo T, Tajiri M, Ohmori T, Ogura T, et al. Early growth response-1 induces and enhances vascular endothelial growth factor-A expression in lung cancer cells. Am J Pathol. 2010; 177:70-83.
46. Shen C, Wang D, Liu X, Gu B, Du Y, Wei FZ, Cao LL, Song B, Lu X, Yang Q, Zhu Q, Hou T, Li M, et al. SET7/9 regulates cancer cell proliferation by influencing β-catenin stability. FASEB J. 2015; 29:4313-23. doi: 10.1096/fj.15-273540.
47. Lezina L, Aksenova V, Ivanova T, Purmessur N, Antonov AV, Tentler D, Fedorova O, Garabadgiu AV, Talianidis I, Melino G, Barlev NA. KMTase Set7/9 is a critical regulator of E2F1 activity upon genotoxic stress. Cell Death Differ. 2014; 21:1889-1899.
48. Francis NJ, Rowlands M, Workman P, Jones K, Aherne W. Small-molecule inhibitors of the protein methyltransferase SET7/9 identified in a high-throughput screen. J Biomol Screen. 2012; 17:1102-1109.
49. Lin J, Qin X, Zhu Z, Mu J, Zhu L, Wu K, Jiao H, Xu X, Ye Q. FHL family members suppress vascular endothelial growth factor expression through blockade of dimerization of HIF1a and HIF1β. IUBMB Life. 2012; 64:921-930.
50. Zhang H, Xie X, Zhu X, Zhu J, Hao C, Lu Q, Ding L, Liu Y, Zhou L, Liu Y, Huang C, Wen C, Ye Q. Stimulatory crosstalk between NFAT3 and estrogen receptor in breast cancer cells. J Biol Chem. 2005; 280:43188-43197.